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Abstract 
T 
Allogeneic hematopoietic stem cell transplanta-
tion (HSCT) is currently the only curative therapy 
for the severe hematopoietic complications 
associated with Fanconi anemia (FA). In Germany, 
it is estimated that 10-15 transplants are per-
formed annually for FA. However, because FA is a 
DNA repair disorder, standard conditioning regi-
mens confer a high risk of excessive regimen-re-
lated toxicities and mortality, and reduced inten-
sity regimens are linked with graft fai lure in 
some FA patients. Moreover. development of 
graft-versus-host disease is a major contributing 
factor for secondary solid tumors. The relative 
rarity of the disorder limits HSCT experience at 
any single center. Consensus meetings were con-
vened to develop a national approach for HSCT in 
FA. This manuscript outlines current experience 
and knowledge about HSCT in FA and, based on 
this analysis, general recommendations reached 
at these meetings. 
Introduction 
T 
Fanconi anemia (FA) is a ra re inherited genomic 
instability disorder associated with congenital 
abnormalities, progressive bone marrow failure 
(BMF). and a predisposition to develop malignan-
cies including myelodysp lastic syndrome (MDS )/ 
acute myeloid leukemia (AML) and squamous cell 
carcinoma (SCC) (23,41 ]. Although there is phe-
notypic variability among FA individuals. hema-
tologic abnormalities arise in the majority of pa-
tients and represent a significant clinical feature 
of the disorder. Some FA patients have mild 
hematologic changes and do not require thera-
Zusammenfassung 
T 
Die allogene Stammzelltransplantation (HSCT) 
ist zurzeit die einzige kurative Therapie der 
schweren hamatopoetischen Komplikationen 
der Fanconi-Anamie (FA). In Deutsch land werden 
etwa 10-15 Trans plantationen pro Jahr bei Pa-
tienten m it FA durchgefiih rt. Da die FA auf einem 
Defekt der DNA-Reparatur beruht, ,konnen 
Standard-Konditionierungsprotokolle zu hoher 
Toxizitat und Mortalitat fiihren, wa hrend Regime 
mit reduzierter lntensi tat ein Risiko fiir Trans-
plantatversagen in sich tragen. Hinzu kommt, 
dass die Entwicklung der Transplantat-gegen-
Empfanger-Erkrankung ein wichtiger Risikofak-
tor fiir die Entwicklung von sekundaren soliden 
Tumoren ist. Die relative Seltenheit der Er-
krankung fiihrt dazu, dass die Erfahrung jedes 
einzelnen Transplantationszentrums mit der Er-
krankung begrenzt ist. Konsensus-Treffen mit 
dem Ziel de r Entwicklung eines bundesweiten 
Vorgehens bei der Transplantation der FA w ur-
den abgehalten. Dieses Manuskript beschre ibt 
die langjahrige Erfahrung und den aktuellen 
Kenntnisstand zur Transplantation bei FA sowie 
den darauf basierenden Konsens, der auf diesen 
Treffen erzielt wurde. 
peutic intervention. Others have moderate to 
severe BMF that improves with androgen therapy 
(60]. In patients with BMF who fail to respond to 
androgens or who develop myeloid neoplasia, 
allogeneic hematopoietic stem cell transplan ta-
tion (HSCT) can restore normal hematopoiesis. 
Unfortunately, early FA HSCT preparative regi-
mens (cyclophosphamide±radiation) based on 
HSCT for patients w ith acquired severe aplastic 
anemia (SAA) were fraught w ith severe compli-
cations (25, 27 ,28, 31, 32,45 ]. Excessive regimen-
related toxicities (RRT), high rates of graft failure, 
graft-versus-host-disease (GVHD), secondary 
cancers, and poor survival outcomes were ob-
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served. These were attributed to underlying congenital abnor-
malities, hypersensitivity to DNA damaging agents and puta-
tively radiotherapy. delayed or absent tissue repair after GVHD 
induced injury, and/or presence ofT cell mosaicism in some FA 
individuals.125,27,28, 31.32.45 ]. 
Over the past 3 decades. modifications to FA HSCT condition ing 
regimens together with advances in transplant medicine (e.g. 
more accurate HLA typing. better supportive care. graft process-
ing, etc.) have dramatically improved the prognosis of FA HSCT 
120]. Reduction of chemotherapy and radiation doses (reduced 
intensity conditioning) lessened RRTs 127,63 J. Incorporation of 
nudarabine to preparative regimens enhanced immunosuppres-
sion and engraftment without adding toxicity l8.29.39,68J. In 
vivo and/or ex vivo T cell depletion of allografts decreased the 
incidence and severity of GVHD 18. 17J. Radiation was eliminated 
in some conditioning regimens with excellent results 148. 54 J. 
For some FA HSCTs, particularly in HLA matched sibling donor 
(MSD) transplants. survival now ranges from 70-100 % with low 
graft failure and GVHD rates l48J. 
Challenges. however. remain. For FA patients who do not have a 
MSD and receive transplants from either mismatched related or 
unrelated donors, collectively termed alternative donor (AD). 
the outcomes of HSCT are less encouraging, albeit improving 
l68J. FA patients with advanced MOS or AML have a poorer prog-
nosis 12). Post- transplant infections represent a leading cause of 
transplant related morbidity and mortality I 1 OJ (Chao et al. in 
press ). Long- term follow-up of FA patients indicate a 4.4 fold in-
creased risk of developing head and neck sec after HSCT l59J. 
associated with GVHD development and debatably radiation ex-
posure I 15, 32,59J. These challenges provide incentive for fur-
ther improvements in FA HSCT. 
Overview of FA HSCT nationally and internationally 
,, 
The first HSCTs for FA in Germany were completed at the Univer-
sity of Ulm in the mid- 1980s. Whereas the initial conditioning 
regimens included total body irradiation (TBI ) or total lymphoid 
irradiation (TLI ), since 1991, radiation has been eliminated. To 
date. 14patients 16 matched unrelated (MUD). 5 MSD. 2 matched 
related transplants (MRD). and one haploidentical transplant! 
have received a cyclophosphamide fludarabine based regime n 
without radiation at the University of Ulm. Busulfan was a lso 
administered in patients with clonal disease and in the haplo -
identical transplant and anti- lymphocyte therapy with alemtu-
zumab (Campath- lH ) or anti- thymocyte globulin (ATC) was 
applied in all patients except in those receiving MSD trans-
plants.10 of the 14 patients are alive. but unfortunately. 2 of the 
surviving patients are suffering from carcinomas. 
Between October 1999 and April 2014. the Pediatric Blood and 
Marrow Transplantation Department at Cha rite University Med-
icine Berlin completed 39 consecutive MSD (n • 4 ) and AD 
(n =35) HSCTs for FA. These transplants account for the majority 
of FA HSCTs performed in Germany. HSCT regimens titled 
German Fanconi Anemia 02 (GEFA02) (n= 18)and German Fanconi 
Anemia 03 (GEFA03) (Chao et a l. in press) (n = 2 1 ). consisting of 
fludarabine based non- radiation conditioning. were utilized. 
The GEFA02 preparative regimen included fludarabine 30 mg/ 
m2/day IV x 6 days, busulfan 1 mg/kg/day in 2 divided doses 
POx2 days, ATC-Fresenius 20mg/kg/day 1Vx3 days, and Mu-
romonab-CD3 (OKT3, Orthoclone OKT3) 0.1 mg/kg/day IV x 12 
days and was employed from 1999 to 2005. Since 2005 to the 
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present time, the GEFA03 regimen which includes fludarabine 
30mg/m2/day JVx 6 days, busulfan 1 mg/kg/day in 2 divided dos-
es PO x 2 days, cyclophosphamide 20 mg/kg/day IV x 2 days, and 
alemtuzumab 5mg/m2/dayxl day fo llowed by 10mg/m2/day 
IV x 3 days has been used. Patients received Cyclosporine A (CSA) 
for GVHD prophylaxis. In this series. all but one patient experi-
enced neutrophil engraftment. Mixed chimerism was observed 
in 4 patients who all converted to full donor chimerism after 
stem cell boost(s), and 4 second transplants were undertaken for 
graft failure. Approximately 38 % of patients developed grade I 
acute GVHD (aGVHD). 10 % grade II aGVHD, and no grade Ill-IV 
aGVHD was observed. Among the eva luable patients. 17% devel -
oped mild chronic GVHD (cGVHD) and no patient experienced 
moderate or severe cGVHD. 11 patients died: 8 from viral infec-
tion. 2 from AML disease progression. and one from SCC. The 
2-year probability of survival was 76% (SE 7%) with a median 
follow-up of 5. 7 years. A sub-analys is of GEFA03 patients showed a 
2-year probability of survival of 90%, 100 % neutrophil engraft-
ment. 38% grade I aGVHD and no grade 11-IV aGVHD. and no mod-
e rate or severe cGVHD. 
At Eberhard Karl University in Tuebingen. 7 pediatric patients 
were transplanted for FA in more recent years. There were 4 
MUD. 2 MSD. and one haploidentical donor transplants. The 
conditioning regimen included fludarabi ne 40 mg/m2/dose x4 
doses, cyclophosphamide 300mg/m2/dose x4 doses. and ATG 
Thymoglobulin 4.5 mg/kg total dose (0.5-2-2 mg/ kg). For MUD 
transplants the dose of ATG was increased to 10mg/ kg (1-3-
3- 3 mg/ kg). For the haploidentical transplant, 15 mg/kg ATG-
Fresenius ( 1- 4-5- 5 mg/kg) was used and 4 Cy TBI. followed by a 
TCRa~/CDl 9 negative depleted allograft of PBSCs. For MSD and 
MUD transplants. the GVHD prophylaxis included CSA and my-
cophenolate mofetil (MMF) and for the haploidentical trans-
plant the patient received only MMF. All patients engrafted. 3 pa-
tients experienced aGVHD and among these patients. 2 developed 
grade I aGVHD and one grade Ill aGVHD. To date, only one patient 
has developed mild cGVHD. The overall survival was 100 %. 
The German experiences recapitulate worldwide FA HSCT 
experiences (e.g. a retreat from radiation based conditioning, 
utilization of fludarabine and anti-lymphocyte antibodies. and 
use of new stem cell sources such as haploidentical donors ). Cur-
rent conditioning regimens used in Germany are comparable to 
preparative regimens employed by others elsewhere and confer 
good outcomes. FA HSCT results published in the past 5 years are 
detailed in o Table 1 11.4. 12. 19, 34,46-48, 62,65, 67. 70. 71 ). 
Radiation vs. no rad iation 
,, 
Historically, radiation was used in FA HSCT preparative regimens 
to facilitate engraftment. Yet, the early use of standard dose ra-
diation was associated w ith severe adverse side e ffects and ini-
tial studies suggesting a marked hypersensitivity of FA patients 
towards radiation led to significant reduction of the radiation 
dose 125,27]. Elimination of the modality proved successful in 
MSD t ransplants. Here, graft failu re was less problematic and 
radiation was omitted without compromising engraftment. In 
mismatched and unrelated donor FA HSCTs. radiation was 
replaced by busulfan in some centers with good results 112]. 
Other centers have continued to employ radiation at lower doses 
for mismatched and unrelated donor transplants, arguing that 
s ingle fraction low-dose radiation confers minimal toxicities not 
exceeding busulfan related toxicities 147,48]. In Germany, radia-
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Table 1 FA HSCT results published over last S years. 
R~erence Condit ioning GVHO Proph y No. of Cases Median Eng raft- aGVHO cGVHD Survival 
Regimen Age m ent' 
Ayas et al. 201211 I Cy, Flu, ATG CSA 26 (19 MRD, 7 UCB) 7.8yrs 19/19. 1/19. 
1/7 
1/8 
1/19. 
1/7 
0/8 
100%, 
43%0S 
100%0S 
2/7 
Shimada et al. 
20121621 
Cy, Flu, ATG CSA, MTX; 8 (3 MSD, 1 MRD, 4.Syrs 8/8 
FK506, MTX 2 MUD, 2 MMUD) 
Yabeetal. 20121701 Cy, ATG, TAl/TBI; CSA, MTX 15(MSD) 8yrs 14/15 1/ 15 3/14 80%0S 
Cy, Flu, ATG 
Cy, Bu, Flu, ATG 27(AD) 27/27 3/27 83%0S Boulad et al. 
20121121 
MacMillan et al. 
20121461 
Cy, ATG. TBI. ±Flu 127(AD) 18-50% 
grade 
II-IV 
4/6 
14/17, 
11/24 
9-25% 61% 1 yr 
POS; 54% 
Syrs POS 
50%0S 
35%, 83% 
OS 
CSA, MMF 6(AD) Thaker et al. 2011 [671 
Stepensky et al. 
Flu, TBI 
Cy, ±TAI/ CSA; CSA. MMF; 
Dae; CSA, Dae; 
FK506, MMF, 
Dae 
41 (MSD,AD; 10.3yrs 
5/6 
17/17, 
22/24 
3/5 
4/17, 
8/24 2011 [651 TU, ±Bu, ±ATG; 
Flu ±Cy, ±Bu, 
±ATG/Atgam, ±TBI 
Cy, Bu, ±ATG; Cy, 
Flu,ATG 
17 w/o Flu, 24 w/ Flu) 
Hamidieh et al. 
2011 [341 
MacMillan et al. 
2010 [48) 
MacMillan et al. 
2009 [471 
CSA±MTX 53 (MSD, MRD, MMRD; 9yrs 49/53 79%, 17%, 
36% 
0% 
61%05 
42 w/o Flu, 11 w/ Flu) 45% 
Cy. Flu. ATG 22 (MSD) 8.Syrs 22/22 0% 82%0$ 
Cy, Flu, TBI, ATG CSA 24 (AD; 22 w/ 3 Gy TBI, 8.Byrs 22/22, 3/22. 86%, 
100%0$ 
87.5% OS 
80%05 
50%. 90% 
OS 
2 w/ l.5GyTBI) 0/2 0/2 
8(MSD) 12 yrs 8/8 0/8 Ertem et al. 2009 [ 191 
Baker et al. 2009141 
Yesilipek et al. 
Cy, Bu; Cy, Au, ATG 
Cy, Flu, ATG, ±Bu 
Cy. TAI, ATG; Cy, 
Flu, ATG 
CSA, MTX 
CSA, MP 
CSA±MMF 
5(MRD. MUD) 4 /5 2/5 
1/8 
0/5 
16 (MRD. MUD; 
2009 (71) 6 TBI, 10 Flu) 
·. primary stable engraftment: Cy, cydophosphamide: Flu, fludarabine: ATG, anti·thymocyte globulin; CSA, cyclosporine A: MRD. matched related donor: UCB, unrelated cord 
blood: OS. overall survival: POS. probability of survival: MTX, methotrexate: MSD. matched sibling donor; MUD, matched unrelated donor: MMUO. mismatched unrelated donor: 
TAI. total abdominal irradiation; TBI, total body irradiation; MMF, mycophenolate mofetil; TU, total lymphoid irradiation; Bu. busulfan; Dae. daclizumab: MP: methylprednisolone 
tion has been omitted for MSD. MUD, and mismatched unrelated 
donor FA HSCTs (excluding some haploidentical transplants). 
In terestingly. conflicting experimenta l and clinical data regard-
ing the radiosensitivity of FA has emerged. While Marcou et al. 
demonstrated normal colony survival assays in irradiated fibro-
blasts from a FA patient, Djuzenova et al. using the same pa-
tient's fibroblasts showed increased DNA damage after radiation 
exposure [ 16,49 I. The patient experienced severe toxicities after 
radiotherapy for tonsillar carcinoma (49). A newer study dem-
onstrated that primary fibroblasts from patients with mutations 
in FANCA. FANCD2. and FANCG are not pa rticularly sensitive for 
either ionizing or UV radiation [37). Moreover, older studies 
clearly implicated radiation in the development of post-trans-
plant head and neck sec in FA patients (15), but more recent 
studies have not identified this link (55,59). The consensus 
group addressed the question whether radiation might be rein-
troduced in future German FA transplant protocols. The group 
agreed to continue with non-radiation protocols based on 
(a) established experience with non-radiation FA HSCT proto-
cols. (b) good results achieved with these protocols. (c) potential 
to eliminate any possible short- and long-term toxicities associ-
ated with radiation, and (d) recent large FA HSCT reviews sug-
gesting inferior survival for FA patients treated with radiation-
containing preparative regimens (3,55 ). 
The backbone 
~ 
Early FA HSCT conditioning regimens consisted of cyclophos-
phamide (200mg/kg) and radiation. With increasing experience, 
there have been refinements to the conditioning regimens. A 
5-10 fold reduction in the cyclophosphamide dose was insti-
tuted. Likewise, radiation was decreased in dose or eliminated. 
Kapelushnik et al. were the first to report the use of fludarabine 
in FA HSCT (391. Subsequently, numerous studies demonstrated 
that fludarabine accorded engraftment and survival benefits. 
Currently, fludarabine based regimens are regarded as standard in 
FA HSCTs [8, 14.65]. Dose reduction of fludarabine, however, is 
warranted in FA patients with renal compromise (personal com-
munication with W. Ebell ). Might there be additional 
modification(s) to the FA HSCT preparative regimens to further 
reduce RRTs? 
In 2007. Bonfim et al. reported on 43 FA patients who received 
transplants from HLA-matched related donors (11 ). The condi-
tioning regimen consisted of cyclophosphamide alone ( total 
dose 60mg/kg). 40 patients (93%) were alive with a median fol-
low-up of 3.7 years. One patient experienced primary graft fail-
ure and 4 patients developed late graft failure. Grade 11-111 
aGVHD and cGVHD were noted in 17 and 28.5 % of patients. re-
spectively [ 11 ). A recently completed phase I/ II study at Baylor 
College of Medicine in Houston. Texas, USA examined alemtu-
zumab and anti-CD45 antibodies (YTH-24 and YTH-54) (10/ 10 
HLA matched) or alemtuzumab, anti-CD45 antibodies, and 
fludarabine (9/10 HLA matched) conditioning in 5 pediatric pa-
tients with FA or other DNA breakage/chromosomal instability 
syndromes (5 I). For HLA mismatched donors. harvested periph-
eral blood stem cells (PBSC) were enriched for CD34+cells (51 ). 
2 of the 5 participants showed donor engraftment at day + 100. 
Median time to ANC >500/mm 3 was 15 days. No aGVHD grade 
II -IV or cGVHD was observed and all patients are alive at one 
Chao MM et al. Consensus of German Transplant ... Klin Padiatr 2015; 227: 157- 165 
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year post-transplantation 151 ]. At Boston Children's Hospital. 
Boston. Massachusetts. USA 4 patients with dyskeratosis congen-
ita were successfully transplanted with matched unrelated donor 
allografts ( ~ 9/10 HLA matched) using nudarabine and alemtu-
zumab 143). All patients engrafted neutrophils by day + 30, and 
are alive and transfusion independent with a follow-up ranging 
from 6 months ( 1 patient) to 2 years (3 patients) 143]. All pa-
tients showed full donor myeloid chimerism by day +60. 3 of the 
4 patients s howed full donor lymphoid chimerism by year 2, and 
the fourth patient has high and increasing mixed donor lym-
phoid chimerism at day + 180. There was no aGVHD and only 
one patient developed limited cGVHD of the skin 143). Whether 
nudarabine and alemtuzumab only preparative regimen might 
be effective in FA HSCT is yet to be established. 
Based on these and other published data and the German expe-
rience. particularly GEFA03, the consensus group agreed that 
nudarabine, cyclophosphamide. and busulfan will continue as 
the backbone agents: however. busulfan may be excluded in 
some transplants. Busulfan is unlikely to be necessary for "low 
risk" transplants (i.e. ~9/10 HLA matched related or unrelated 
HSCTs with BMF). Busulfan may be beneficial in FA patients with 
mismatched allografts to assist engraftment. and as an anti-leu-
kemic agent in FA patients with bone marrow clonal aberration(s) 
and/or MDS/AML. Intravenous busulfan is preferred over oral 
busulfan due to its more consistent pharmacokinetics. 
In vivo T cell depletion: Anti-thymocyte globulins vs. 
alemtuzumab 
,, 
Both ATG(s) and alemtuzumab have been applied as in vivo T 
cell depleting agents in FA HSCTs to aid engraftment and to re-
duce the incidence and severity of GVHD. Whether one lympho-
cyte-depleting antibody may be advocated over the other is dif-
ficult to answer, as there are no prospective direct comparison 
studies in FA. Charite University Medicine Berlin used ATC-Fre-
senius with OKT3 in the GEFA02 protocol and alemtuzumab in 
the GEFA03 protocol. Comparison ofGEFA02 and GEFA03 results. 
with the caveat that the backbone agents were not identical, 
demonstrated more stable engraftment (5/18 vs. 0/21 graft fail-
ure or mixed chimerism requiring stem cell boosts), less fatal 
viral infections (6/18 vs. 2/21 ), and a higher overall survival rate 
(10/18 vs. 18/21) with GEFA03. Moreover, published reports in 
other diseases and adult patients suggest superior outcomes 
with alemtuzumab. Marsh et al. retrospectively compared pa-
tients with acquired SAA who were conditioned for allogeneic 
HSCT with regimens including alemtuzumab (n = 100) or ATG 
(n =55) [50]. Engraftment failure occurred in 9 and 11 % of pa-
tients in the alemtuzumab and ATG groups, respectively. The 
5-year survival rate was 90% for alemtuzumab and 79% for ATG. 
Overall survival was significantly better when using alemtu-
zumab (88 %) compared with ATG (57%, p =0.026) for unrelated 
donor transplants. The risk for cGVHD was lower in the alemtu-
zumab group (11 vs. 26%, p =0.03 1) [50] . Similarly. Soiffer et al. 
examined the outcomes of reduced intensity conditioning trans-
plants according to the use of in vivo T cell depletion with ATG 
(n=584). alemtuzumab (n=213). or no antibody therapy 
(n =879) in patients with hematopoietic malignancies 164 J. Both 
grade 11- IV aGVHD and cCVHD incidences were lower with 
alemtuzumab compared with ATC and unmanipulated grafts 
(19 vs. 38 % for ATC and 40% for unmanipulated grafts. p <0.0001 
and 24 vs. 40 % for ATG and 52 % for unmanipulated grafts, 
Chao MM et al. Consensus of German Transplant ... Klin Padiatr 2015; 227: 157- 165 
p<0.0001. respectively) 164]. Relapse was more frequent with 
alemtuzumab and ATC ( 49 and 51 %, respectively, vs. 38 % unma-
nipulated, p <0.001 ). The 3-year probability of survival after ad-
justing for age, performance status, disease, disease status, 
CVHD prophylaxis, and donor source were SO% for alemtuzum-
ab, 46% for T cell replete, and 38 % for ATC containing regimens. 
The difference in survival outcomes between alemtuzumab and 
T cell replete groups was not statistically significant but the dif-
ference between ATG and unmanipulated T cell replete grafts 
was significant (p =0.008 ) [64]. Lower incidences of CVHD and 
RRTs and their sequelae related with alemtuzumab administra-
tion may explain the improved survival rates [ 4 7] . Of signifi-
cance for FA patients is the lower rate ofCVHD afforded by alem-
tuzumab. since its development is associated with a higher risk 
for secondary malignancy IS91 and a negative impact on the 
quality of life. 
Other GVHD prophylaxis 
,, 
In a retrospective review of patients with FA (n =37) or acquired 
aplastic anemia (n = 73) following MSD HSCT, FA patients had 
double the relative risk of grades II-IV aGVHD (p = 0.021 ), and in 
younger patients. the relative risk was 7.93 (p=0.014) [32]. 
Moreover. the risk of requiring systemic corticosteroids and ex-
periencing steroid-resistant aGVHD was higher in FA patients 
[32]. Increased cellular apoptosis in FA individuals has been 
linked to the higher severity of aGVHD l69J. Wang et al. assessed 
epithelial cell apoptosis and studied TP53 and miR-34a expres-
sion in the skin and gut biopsies from S non-transplanted FA pa-
tients, 20 FA patients with aCVHD, and 25 acquired aplastic ane-
mia patients. Although FA and aplastic anemia patients received 
similar preparative regimens, epithelial apoptosis was higher in 
FA specimens than in samples from patients with acquired 
aplastic anemia patients [69]. Further studies of gut biopsies 
from FA patients showed that this delete rious effect was not re-
lated to TPS3 gene overexpression but rather miR-34a which 
mimics pS3 apoptotic effects in response to DNA damage [69]. In 
a large analysis of 795 FA HSCTs between 1972 and 2009, the 
incidence of cCVHD was 14% at 1 year and 19% at S years IS5]. 
Older age at transplant and history of aCVHD were independent 
predictors of cCVHD [SS]. The development of cCVHD correlated 
with an increased risk of developing head and neck SCC [S9[. A 
principal goal in FA HSCT has been to reduce the incidence and 
severity of CVHD in order to abolish any of its potential short-
and long-term complications. In addition to anti-lymphocyte 
antibody to reduce the incidence and severity ofCVHD. the con-
sensus group advises CSA as CVHD prophylaxis, with the addi-
tion of M MF for unrelated donors. 
Immune reconstitution 
,, 
Allogeneic HSCT is associated with profound immune deficiency 
owing to a multitude of factors including underlying disease, 
transplant conditioning regimen, stem cell source, degree of HLA 
matching. graft manipulation, development ofCVHD, immuno-
suppressive medications for CVHD prophylaxis/therapy, and 
others. However, the speed of immune recovery has important 
repercussions regarding infectious complications and relapse 
following allogeneic HSCT 121,401. The consensus group ad-
dressed post-transplant immune reconstitution as related to the 
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anti-lymphocyte antibody utilized in the preparative regimen. 
The focus was on alemtuzumab since the antibody is proposed 
for future studies. 
There is evidence that alemtuzumab is more immunosuppres-
sive than ATC because the former is directed against a variety of 
immune cells including T and B cells, macrophages, monocytes, 
and NK cells and the latter targets mainly T lymphocytes l57j. In 
a comparison of immune reconstitution following alemtuzumab 
(n=14) or ATC (n= 13) in pediatric unrelated transplants, pa-
tients who received alemtuzumab demonstrated significantly 
slower immune recovery (61 j. The presence of peripheral blood 
CD3 +T cells ( > 30cells/µL) (64.5 vs. 27 days). the median time to 
normal phytohemagglutinin response (2S3 vs. SS days). and the 
median time to an antigen specific response (365 vs. 150 days ) 
occurred later in those receiving alemtuzumab in comparison to 
patients given ATC [61 j. Despite these delays in immune recov-
ery, there was no increase in infectious complications in recipi-
ents of alemtuzumab 161 ]. 
Total lymphocyte and lymphocyte subset counts in peripheral 
blood were evaluated in the 39 patients who received CEFA02 
(ATC/OKT3) and CEFA03 (alemtuzumab) preparative regimens. 
There was large patient-to-patient variability related to the clin-
ical circumstance of the patient: however, as a group, total lym-
phocyte counts steadily rose and by day + 100 the mean value 
was 1166/µL NK cells were present at normal numbers immedi-
ately following transplantation and accounted for the majority 
of lymphoid cells during the early post-transplant period. B cells 
reached normal levels by day + 60. CDS+ cells recovered by 3 
months. CD4+T cells were considerably slower to recover and 
the CD4 +to CDS+ ratio remained < 1 in the majority of patients 
during the first year following transplantation. CD4 +reached 
normal levels by day +365. Memory (CD45RO+) helper (CD4+) 
and cytotoxic (CDS+ )Tcells predominated over nalve(CD45RA+) 
T cells during the one-year analysis period. Comparison of 
CEFA02 and CEFA03 immune reconstitution data showed mod-
estly higher lymphocyte values for CEFA03 patients that were 
not statistically significant for most of the analyzed time points. 
This pattern of post-transplantation immune reconstitution is 
similar but not identical to reports by others [24, 56 ]. In FA pa-
tients following HSCT, Perlingeiro et al. found a slightly different 
kinetic of recovery in the major lymphocyte subsets in 23 pa-
tients conditioned with one of 3 regimens (fludarabine. cyclo-
phosphamide and ATC, cyclophosphamide alone, or fludarabine 
and irradiation) for related and unrelated donor transplants [56j. 
NK cells were the first to recover, followed by cytotoxic CDS+ T 
cells and B cells, and finally CD4+T cells. Early lymphocyte re-
covery consisted of memory cells potentially derived from the 
graft. New thymic emigrant (CD31 +CD45RA+) and naive 
CD4+or CDS+T cells rose only at 6 months after HSCT. Only 
marginal differences were observed in the early recovery of 
CDS+ T cells among those receiving a graft from a related donor 
versus an unrelated donor. Patients with CVHD displayed a 
markedly delayed recovery of NK cells and B cells as well as of 
regulatory T cells and both early thymic emigrant and total 
CD4 + T cells [56 ]. Nonetheless. viral infection represented a ma-
jor complication following FA allogeneic transplantation [ 10j. In-
deed, in the Charite University Medicine Berlin cohort (n=39), 
viral reactivation/infection involving CMV. human herpes virus 6, 
Epstein-Barr virus (EBV), adenovirus, and combined viral infec-
tions. were the leading causes of death (8/11 ). 
A logical response to improve post-transplant immune recovery 
may be to decrease the dose of alemtuzumab. A wide range of 
doses (100-lOmg total dose) of alemtuzumab has been em-
ployed in allogeneic HSCT [3S.57]. Chakraverty et al. examined 
de-escalating doses of alemtuzumab in reduced intensity condi-
tioning regimen with fludarabine and melphalan in 106 adult 
MSD transplants [ 13]. The 20 mg total dose of alemtuzumab was 
associated with a greater risk of grade Ill-IV aCVHD and severe 
cCVHD in comparison with doses > 20mg. A total dose of 20 mg 
or lower was linked with incomplete saturation of CD52 binding 
sites. more rapid clearance, and greater risk of severe acute and 
chronic CVHD [13,57]. A total dose of 30 mg or lower was associ-
ated with a significant decrease in alemtuzumab levels by day 28 
[13.57j. The 30mg dose resulted in comparable CVHD outcomes 
but better lymphocyte recovery at one year post-transplantation 
than the 40 mg or 60 mg dose groups [ 13 ]. However, improved 
lymphocyte counts were not associated with lower rates of in-
fections (13). Bertz et al. reported no difference in grade Ill -IV 
aCVHD and extensive cCVHD or graft failure in 127 patients 
who received 10, 20, or 40mg (total dose) alemtuzumab for un-
related transplants [7]. There was a significant difference in 
grade II-IV aCVHD incidence between the 20 and 40 mg dose 
cohorts [7]. In summary, the standard total dose of 100 mg ap-
pears more than is required in most transplant settings. Doses of 
less than 30 mg may be insufficient and predispose to increased 
risks of CVHD [57], however, comparative analyses of data from 
published literature are difficult due to differences in patient 
populations. diseases treated, and preparative regimens. Still 
more, the clinical benefit (i.e. decreased infections) is unclear. 
Finally, Bokhari et al. reported increased incidence of EBV in-
duced post-transplant lymphoproliferative disease (PTLD) fol-
lowing a reduction in alemtuzumab dose from 50 to 30mg [9]. 
For comparison, the alemtuzumab dose of 35 mg/m2 ( 1.16 mg/ 
kg) used in CEFA03 resulted in a median total dose of 35 mg and 
mean total dose of 38mg (range 11-75mg). Other reduced in-
tensity conditioning regimens for HSCT in patients with chronic 
granulomatous disease or DNA breakage repair disorder use 
alemtuzumab doses ranging from 0.5 mg/kg to 1 mg/kg [30, 33]. 
The consensus group agreed to an alemtuzumab dose of 30mg/ 
m2 ( 1 mg/kg), since further dose reductions appear not to pro-
vide anti-infection benefits and may increase the risk of GVHD. 
A decreased alemtuzumab dose of 20mg/m2 may be employed 
in patients with MSD allografts ( 10/10, genotypically identical). 
only of BM is used as stem cell graft. In patients with MSD allo-
grafts (~9/10) and PBSC grafts, total alemtuzumab dose should 
remain 30mg/m2, due to increased risk ofCVHD. The group also 
advocates prophylaxis and strict surveillance of infections, 
preemptive therapy and aggressive early treatment. 
Selective allodepletion of the graft may be one method to im-
prove immune reconstitution following allogeneic HSCT. 
CD34+positive selection of stem cell grafts enabled rapid and 
sustained engraftment. but immune reconstitution was delayed 
due to non-discriminate reduction of T cells in donor grafts [5 ]. 
Development ofCD3, CD3/CD19 and more recently TCRaP/CDl 9 
depletion strategies allow for T cell depletion of allografts with 
preservation of immune effector cells such as NI< cells, mono-
cytes, dendritic cells, and yo T cells to improve immune recovery 
and to better exploit graft versus malignancy effects [35]. In a 
randomized study of MSD and unrelated donor transplants, 
faster NK cell recovery was observed in patients with CD3/CD19 
depleted PBSC grafts as compared with the CD34 positive selec-
tion patients [35j. Lang et al. recently reported on the results of 
35 patients with high-risk malignant and nonmalignant disor-
ders transplanted with TCRaP/CDl 9 depleted haploidentical 
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grafts. Within the first month post- transplantation, rapid 
imm une reconstitution with good levels of CD3 + T cells, 
CD3+CD4+T cells, and CD56+NK cells was observed (42). In 
addition, expansion of TCRyo+ T cells occurred faster than 
TCRap+ T cells in the early post-transplant period and may con-
tribute to anti-infectious and anti-tumor immunity [42,44,53). 
Graft engineering technologies may benefit FA patients, espe-
cially if they receive a mismatched PBSC allograft. 
Haploidentical transplantation 
... 
In patients who lack an HLA matched related or unrelated donor, 
haploidentical stem cell transplantation is a feasible alternative. 
The immediate availability of a haploidentical donor in most 
families and the possibility for post-transplant cellular therapies 
either in the prevention of relapse or treatment of viral infec-
tions by adoptive T cell transfer are advantages of this type of 
transplantation (52(. Haploidentical HSCTs have been under-
taken for both malignant and nonmalignant disorders since the 
late 1970s [6,22,58). In a recent publication, Zecca et al. report-
ed on 12 FA patients who were given T cell depleted. CD34 + pos-
itively selected cells from a haploidentical related donor after a 
reduced intensity conditioning regimen including fludarabine 
(120mg/m2 ). cyclophosphamide (1 200 mg/m2 ), ATC-Fresenius 
(40mg/kg) with and without radiation (2Gy TBI) [72). Engraft-
ment was achieved in 9of12 patients (75 %) and the cumulative 
incidence of graft rejection was 17% (95% confidence interval 
[Cl), 5-59%). The frequencies of grades II-IV aGVHD and cGVHD 
were 17% (95 % Cl, 5-59%) and 35% (95% Cl, 14-89%), respec-
tively. The cumulative incidence of transplant-related mortality 
was 17% (95 % Cl, 5-59%). The 5-year overall survival, event-free 
survival (probability of survival from time of transplant to oc-
currence of any event- graft failure, rejection or death from any 
cause- or the date of last follow up ), and disease-free survival 
(probability of survival without evidence of disease at anytime 
after transplantation) were 83% (95 %CI. 62-100%). 67%(95 % Cl. 
40-93 %), and 83 % (95% Cl, 62-100%), respectively [72). Another 
group published their experience with 3 FA haploidentical 
HSCTs [66). The patients received cyclophosphamide, fludara-
bine, and radiation. All 3 patients engrafted. One patient died 
from infection on day + 37. Of the 2 remaining patients, both 
developed~grade II aGVHD and one patient developed mild cG-
VHD [66). Dufort et al. also reported on 3 FA patients who were 
given fludarabine. cyclophosphamide, ATG, and TLI prior to hap-
loidentical transplantation [ 18). The patients engrafted, did not 
experience GVHD. and are alive at last follow-up (5. 6, and 16 
months ) [18). 
Charite University Medicine Berlin performed one haploidenti-
cal transplant for FA using the GEFA03 conditioning regimen. 
The patient had MOS classified as refractory anemia with 7 % 
blasts and complex karyotype including a chromosome 3 abnor-
mality. He received CD34 +positively selected PBSC from a pater-
nal uncle and engrafted neutrophils and platelets. The patient 
did not experience any aGVHD, but did develop mild cGVHD. 
Approximately 18 months post-transplantation. the marrow 
showed recipient marrow reconstitution and progression to 
AML. The patient subsequently received multiple donor lym-
phocyte infusions, reinduction chemotherapy, and a second 
haploidentical transplant from his 'father. He eventually d ied of 
AML 8 years after the first transplantation. At Hannover Medical 
School Children's Hospital, one FA patient with AML underwent 
Chao MM et al. Consensus of German Transplant ... Klin Padiatr 2015; 227: 157-165 
a paternal haploidentical HSCT. The patient received pre-trans-
plantation therapy with low-dose cytarabine and developed 
prolonged aplasia and pulmonary aspergillosis. The patient 
went on to receive a megadose of CD34+positively selected 
PBSC and granulocyte transfusions until engraftment after con-
ditioning with cyclophosphamide. fludarabine, and ATG. She de-
veloped mild cGVHD involving her skin and is alive and well 15 
years after transplantation. In Tuebingen. one FA patients re-
ceived a haploidentical transplants from a paternal grandmoth-
er. Here, the conditioning regimen included cyclophosphamide, 
fludarabine. ATG, irradiation, and TCRaP/CDl 9 depletion of the 
graft. The patient engrafted neutrophils and platelets. The pa-
tient developed grade I aGVHD but no cGVHD and is alive. Hap-
loidentical transplantation in FA is emerging as an alternative 
therapy for some FA patients. There appears to be more experi-
ence using ATG in this setting. Concepts using post stem cell in-
fusion cyclophosphamide for T cell allodepletion are being de-
veloped for FA patients receiving mismatched allografts includ-
ing haploidentical transplants [66(. 
Cord blood transplantation 
... 
Although the first successful related cord blood transplantation 
(CBT) occurred in a patient with FA [26), there is a paucity of 
information regarding FA patients and CBT. EBMT retrospective-
ly analyzed the results of unrelated cord blood transplantation 
(UCBT) in 93 FA patients from 26 centers worldwide transplant-
ed between 1994 and 2005 [29(. The median age at transplanta-
.tion was 8.6 years. The majority of patients received an HLA mis-
matched cord blood allograft (1 HLA difference 35 cases and 2 or 
3 HLA differences 45 cases). The median number of nucleated 
cells and CD34+cells infused was 4.9x107/kg and 1.9xl05/kg, 
respectively. The transplants were completed using varying pre-
parative regimens; 61 % of patients received fludarabine [29). 
Cumulative incidence of neutrophil recovery was 60±5 % at 
day +60. The incidence of grade II-IV aGVHD and cGVHD was 
32±5% and 16±4%, respectively. Overall survival was 40±5%. In 
multivariate analysis, factors associated with favorable outcome 
were use of fludarabine in the conditioning regimen, ~4.9x107 /kg 
nucleated cells infused, and negative recipient CMV serology 
[29). More recent reports describe small institutional experi-
ences and demonstrate conflicting results. Ayas et al. reported 
on 7 FA patients who received pa rtially matched unrelated cord 
blood grafts. The patients were conditioned with cyclophospha-
mide (5 mg/kg/day for 4 days). fludarabine (30mg/m2/dose for 5 
days). and rabbit ATC (5 mg/kg/day for 4 days) [ 1 j. The therapy 
was generally well tolerated with mucositis and CMV viremia 
representing major therapy-related complications I 1J.4 patients 
failed to engraft and another patient had secondary graft failure 
7 months post-transplantation. One patient developed grade II 
aGVHD of the skin that evolved to cGVHD. At last follow-up 
ranging from 29 to 34 months, 3 patients are alive but only 2 are 
transfusion independent [I). jaing et al. administered fludara-
bine (30mg/m/day for 6 days). cyclophosphamide (60mg/kg/ 
day for 2 days), and rabbit ATG (2.5 mg/kg/day for 3 days) in 3 FA 
patients who received unmanipulated umbilical cord blood 
altografts (36). None of the patients developed significant regi-
men related toxicity and all engrafted within 10-19 days [36(. 
All patients are well with stable or full donor chimerism after a 
median follow-up of 64 months [36). In summary, CBT in FA is 
evolving. 
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Fludarabine (Flu) 30mg/m2/daylV 
·eusulfan (Bu) 0.8mg/kg/dose1V 
Day-9to-4 
Day-6 and -5 
Cyclophosphamide (Cy) 20mg/kg/daylV Day-3 and -2 
'Alemtuzumab (Ale) (5) 10mg/m2/day1V Day - 7 to -4 
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-
Fig. 1 Recommended allogeneic hematopoietic stem cell transplanta · 
tion schema based on GEFA03. •Omit busulfan for low risk patients 
defined as cytopenia without evidence of leukemia or cytogenetic aber· 
rations and with HLA ident ical donor (i.e. "'9/10 MSD. MRD. or MUD). 
Busulfan levels recommended. #Decrease alemtuzumab dose to 20mg/m2 
in patients with MSD allografts (10/10) and only if BM is used as stem cell 
source. In patients with MSD ( S9/l 0), unrelated donor, or PBSC grafts. 
total alemtuzumab dose should remain 30mg/m2• 
The total dose of conditioning drugs Is: fiudarabine l 80 mg/m2• IV busul· 
fan (Busilvex®) 1.6mg/kg. cyclophosphamide40mg/kg. and alemtuzum· 
ab 30 mg/m2 for MUD. MMRD. or PBSC (5 mg/m2 days· 7 and· 6 followed 
by 10mg/m2 days - 5 and · 4) reduced to 20mg/m2 for MSD (5mg/m2 
days· 7 and ·6 followed by 10mg/m2 day -5). 
Conclusions and recommendations 
y 
HSCT represents a curative option for the severe hematological 
complications associated with FA. The therapeutic procedure is, 
however. characterized by unique challenges in this patient pop-
ulation. The consensus meetings on HSCT in FA aims to build 
upon previous German and international experiences and incor-
porate new data and technologies to improve outcomes. The 
current conclusions and recommendations are as follows: 
1. Chemotherapy-only conditioning regimens resulted in equal 
or better outcomes than regimens that included radiothera-
py. also in patients with MDS/AML. There is no reason to re-
introduce radiotherapy into conditioning regimens for FA. 
2. The chemotherapeutic backbone in the German GEFA03 study, 
the ESID-EBMT recommendations. and other modern condi-
tioning therapies consist offludarabine and cyclophosphamide 
[30]. This combination also forms the basis of the current reco-
mmendation. o Fig. 1 illustrates the preparative regimen. 
3. The addition of busulfan to the fludarabine cyclophospha-
mide backbone is probably not necessary in patients trans-
planted for BMF without blood cell clonal aberration(s) and/ 
or MDS/AML, if transplanted from a '?:. 9/10 HLA matched 
related or unrelated donor. 
4. Busulfan is recommended to facilitate engraftment in patients 
with mismatched/haploidentical allografts ( <9/10) and as an-
ti-leukemic agent in patients with bone marrow clonal aberra-
tions and/or MDS/AML. The intravenous formulation is pre-
fe rred due to more consistent blood levels. To gain more 
knowledge about the pharmacology ofbusulfan in FA, pharma-
cological monitoring of busulfan levels is recommended. 
5. To prevent GVHD. in vivo T eel! depletion is recommended in 
all FA patients, including patients transplanted from an MSD. 
Report. 
6. Alemtuzumab is considered superior to ATC in FA patients 
because of its better GVHD prophylactic effect. 
7. In addition to anti-T cell antibody, CSA (day - 1 until 
day + 100. then taper ) is employed for GVHD prophylaxis. 
MMF (day - 1 to day+ 28. then taper ) is added to CSA in un-
related donors only. Continuation or tapering of CSA and 
MMF is dependent on the presence or absence of GVHD. 
8. Bone marrow is preferred as a stem cell source over PBSC 
because of its lower risk for GVHD. 
9. For matched ("?:9/1 O) PBSC grafts, limitation of the total Teel! 
dose of the unmanipulated graft or exvivo reduction of the T 
cell dose may be considered to avoid GVH D. For m ismatched/ 
haploidentical (<9/10) transplants. for T cell depletion is 
mandatory. 
10. Haploidentical transplantation concepts in FA are under 
development; no specific concept can be favored over an-
other at this time. 
11. Because CBT in FA is still evolving, unrelated cord blood as a 
stem cell source is not generally recommended for trans-
plantation of FA patients at this time. 
12. Although most transplant experience stems from HSCTs 
conducted in children with FA. these recommendations are 
inte nded for pediatric and adult patients with the condition. 
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